ReviewCurrent opinion in infectious diseases2011
Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum.
Review in Current opinion in infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Use of malaria RDTs in various health contexts across sub-Saharan Africa: a systematic review.BMC public health · 2017Pooled it
- A clinical and molecular study of artesunate + sulphadoxine-pyrimethamine in three districts of central and eastern India.Malaria journal · 2013Trial
- Immunoinformatics-Based Multi-Epitope Vaccine Design AgainstHealth science reports · 2025Article
- Driving antimalarial design through understanding of target mechanism.Biochemical Society transactions · 2020Review
- Pairwise growth competitions identify relative fitness relationships among artemisinin resistant Plasmodium falciparum field isolates.Malaria journal · 2019Article
- Malaria in India: The Need for New Targets for Diagnosis and Detection of Plasmodium vivax.Proteomics. Clinical applications · 2018Review
- Evaluation of malaria rapid diagnostic test (RDT) use by community health workers: a longitudinal study in western Kenya.Malaria journal · 2018Article
- Novel Immunoinformatics Approaches to Design Multi-epitope Subunit Vaccine for Malaria by Investigating Anopheles Salivary Protein.Scientific reports · 2018Article
- Inhibiting the Plasmodium eIF2α Kinase PK4 Prevents Artemisinin-Induced Latency.Cell host & microbe · 2017Article
- Discovery of Antimalarial Azetidine-2-carbonitriles That InhibitACS medicinal chemistry letters · 2017Article
- Controlling schistosomiasis with praziquantel: How much longer without a viable alternative?Infectious diseases of poverty · 2017Review
- Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase.ACS infectious diseases · 2017Article
- Bibliometric Analysis of Worldwide Publications on Antimalarial Drug Resistance (2006-2015).Malaria research and treatment · 2017Review
- Operational Assessment of Long-Lasting Insecticidal Nets by Using an Anopheles Salivary Biomarker of Human-Vector Contact.The American journal of tropical medicine and hygiene · 2016Article
- Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies.Nature communications · 2016Article
- Transmission-blocking strategies: the roadmap from laboratory bench to the community.Malaria journal · 2016Review
- Design, structure prediction and molecular dynamics simulation of a fusion construct containing malaria pre-erythrocytic vaccine candidate, PfCelTOS, and human interleukin 2 as adjuvant.BMC bioinformatics · 2016Article
- Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum.Nature communications · 2015Article
- Development of a genetic tool for functional screening of anti-malarial bioactive extracts in metagenomic libraries.Malaria journal · 2015Article
- In vivo monitoring of dihydroartemisinin-piperaquine sensitivity in Plasmodium falciparum along the China-Myanmar border of Yunnan Province, China from 2007 to 2013.Malaria journal · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewArtemisinin-based combination therapies (ACTs) have been deployed globally with remarkable success for more than 10 years without having lost their malaria treatment efficacy. However, recent reports from the Thai-Cambodian border reveal evidence of emerging resistance to artemisinins. The latest published clinical and molecular findings are summarized herein. RECENT
findingsClinical studies have identified delayed parasite clearance time as the most robust marker of artemisinin resistance. Resistance has only been documented from South-east Asia and has been observed in isolates that show no significant decrease in drug susceptibility in vitro. Genetic investigations have yet to uncover robust molecular markers. In-vitro studies have identified parasite quiescence or dormancy mechanisms that protect early 'ring-stage' intra-erythrocytic parasites against short-term artemisinin exposure. This might be achieved by reducing the rate of hemoglobin degradation, important for artemisinin bioactivation. SUMMARY: Should ACTs fail, no suitable alternatives exist as first-line treatments of P. falciparum malaria. Intensified efforts are essential to monitor the spread of resistance, define therapeutic and operational strategies to counter its impact, and understand its molecular basis. Success in these areas is critical to ensuring that recent gains in reducing the burden of malaria are not lost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.